Nushmia Khokhar, MD

Chief Medical Officer

Dr. Khokhar was appointed as Chief Medical Officer of Pyramid Biosciences in July 2022. Prior to joining Pyramid Biosciences, she served as Chief Medical Officer at Umoja Biopharma, a multi-platform, immuno-oncology company based in Seattle, WA. In this capacity, Dr. Khokhar oversaw Umoja’s clinical development, operations, and regulatory functions. Prior to joining Umoja, Dr. Khokhar was the Senior Vice President & Head of Clinical Development at Autolus Therapeutics, where she played a critical role in advancing the company’s autologous CAR T-cell products and clinical programs. Prior to that, Dr. Khokhar held numerous roles at Janssen Oncology, a subsidiary of Johnson & Johnson (NYSE: JNJ) where she led several successful clinical trials, directed the Phase 3 registration trial of trabectedin (YONDELIS®) in soft tissue sarcomas, and served as the Global Clinical Leader for the breakthrough therapy daratumumab (DARZALEX®) for hematologic cancers.  Dr. Khokhar is a graduate of Aga Khan University and completed her post-doctoral fellowship at Memorial Sloan-Kettering Cancer Center, where she focused on pharmacology and molecular therapeutics. Following her post-doctoral fellowship, Dr. Khokhar completed a residency in internal medicine at Washington Hospital Center and a fellowship in Hematology/Oncology at the Northwestern University Hospital. Dr. Khokhar is board certified in medical oncology.